Intercept Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Intercept Pharmaceuticals has been growing earnings at an average annual rate of 22.4%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 8.3% per year.

Key information

22.4%

Earnings growth rate

26.2%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	8.3%
Return on equity	-80.0%
Net Margin	-18.1%
Last Earnings Update	30 Sep 2023

Recent past performance updates

Recent updates

Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive

Jun 08

Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Apr 11

Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Dec 20

Intercept touts Ocaliva benefit in transplant-free survival in liver disease type

Sep 20

Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

May 10

Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH

Mar 05

Intercept names Andrew Saik as chief financial officer

Jun 07

Intercept Pharmaceuticals slides as FDA restricts Ocaliva use

May 26

Revenue & Expenses Breakdown

How Intercept Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:ICPT Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 23	318	-57	212	160
30 Jun 23	306	-159	210	163
31 Mar 23	295	-173	196	171
31 Dec 22	286	-175	176	177
30 Sep 22	277	-202	168	187
30 Jun 22	266	-115	166	187
31 Mar 22	263	-120	170	180
31 Dec 21	261	-136	177	183
30 Sep 21	275	-144	200	185
30 Jun 21	288	-193	230	189
31 Mar 21	297	-231	279	185
31 Dec 20	234	-273	261	189
30 Sep 20	301	-321	356	204
30 Jun 20	283	-339	362	216
31 Mar 20	272	-347	339	241
31 Dec 19	252	-345	317	243
30 Sep 19	234	-335	295	241
30 Jun 19	219	-314	275	229
31 Mar 19	196	-318	270	217
31 Dec 18	180	-309	255	207
30 Sep 18	164	-333	265	200
30 Jun 18	159	-341	269	198
31 Mar 18	146	-352	271	195
31 Dec 17	131	-360	270	190
30 Sep 17	107	-369	268	186
30 Jun 17	71	-385	261	175
31 Mar 17	46	-376	239	166
31 Dec 16	25	-413	229	154
30 Sep 16	12	-381	210	131
30 Jun 16	7	-343	181	123
31 Mar 16	2	-314	157	117
31 Dec 15	3	-226	119	113
30 Sep 15	3	-173	71	107
30 Jun 15	3	-158	55	107
31 Mar 15	3	-77	42	94
31 Dec 14	2	-283	35	80
30 Sep 14	2	-261	27	66
30 Jun 14	2	-257	21	47
31 Mar 14	2	-304	16	37
31 Dec 13	2	-68	13	28
30 Sep 13	2	-86	11	23
30 Jun 13	2	-61	8	18
31 Mar 13	2	-53	7	18
31 Dec 12	2	-46	5	16

Quality Earnings: ICPT is currently unprofitable.

Growing Profit Margin: ICPT is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ICPT is unprofitable, but has reduced losses over the past 5 years at a rate of 22.4% per year.

Accelerating Growth: Unable to compare ICPT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ICPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).

Return on Equity

High ROE: ICPT has a negative Return on Equity (-79.99%), as it is currently unprofitable.

Intercept Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Third quarter 2023 earnings: EPS exceeds analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

Intercept Pharmaceuticals, Inc. Receives Complete Response Letter from FDA Addressing OCALIVA Supplemental New Drug Application (sNDA)

Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market

Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT).

Third quarter 2023 earnings: EPS exceeds analyst expectations

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT) for approximately $840 million.

Now 20% undervalued after recent price drop

Now 22% undervalued after recent price drop

Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Price target decreased by 24% to US$15.08

Intercept Pharmaceuticals, Inc. Presents New Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage

Intercept Pharmaceuticals, Inc. Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive

Price target decreased by 14% to US$21.00

Forecast breakeven date moved forward to 2024

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Price target increased by 9.9% to US$24.00

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 8.2% to US$20.85

U.S. Food and Drug Administration Accepts Intercept Pharmaceuticals, Inc.'s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to Nash

Consensus forecasts updated

Forecast breakeven date pushed back to 2025

Intercept Pharmaceuticals, Inc. Resubmits New Drug Application to U.S. Fda for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH

Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Consensus forecasts updated

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Intercept Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid in Compensated Cirrhosis Due to Nash Did Not Meet Its Primary Endpoint

Price target decreased to US$24.00

Intercept Pharmaceuticals, Inc. Announces Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

Intercept touts Ocaliva benefit in transplant-free survival in liver disease type

Intercept cuts debt further with deal to exchange convertible notes

Intercept reduces debt with repurchases of $327.9M convertible notes

Intercept Pharmaceuticals: Too Risky To Buy At This Stage

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Intercept Pharma Q2 2022 Earnings Preview

Intercept Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Consensus forecasts updated

Forecast breakeven date moved forward to 2022

Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)

Intercept to resubmit for FDA approval of NASH candidate after new analysis

Intercept Pharmaceuticals, Inc. Provides Update on Nash Regulatory Timeline

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Intercept: Increase Of Ocaliva Sales And A Few Catalysts

Consensus estimates of losses per share improve by 93%

Forecast breakeven date moved forward to 2022

Intercept Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis

Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

Forecast breakeven date moved forward to 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Intercept Pharmaceuticals, Inc., Annual General Meeting, May 25, 2022

Consensus estimates of losses per share improve by 29%

Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH

Full year 2021 earnings: EPS exceeds analyst expectations